$HRTX News

Last published 2d ago

2d agoHRTXHeron Therapeutics Announces Third Quarter 2026 Financial ResultsGlobeNewswireQ3 2026 net revenue of $35.3 million; ZYNRELEF® net revenue up 13.8% and APONVIE® net revenue up 49.3% compared to the third quarter of 2025Entered into a definitive agreement under which CorMedix Therapeutics will
2d agoHRTXHeron Therapeutics Announces Third Quarter 2026 Financial ResultsGlobeNewswireCARY, N.C., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and nine months ended September 30, 2026 and recent corporate updates ...
2d agoHRTXHERON THERAPEUTICS, INC. /DE/ - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
2d agoHRTX CRMDCorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of CareGlobeNewswireAdds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform
2d agoCRMD HRTXCorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of CareGlobeNewswireAdds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash,
2w agoHRTXHeron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026GlobeNewswireCARY, N.C., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a
3mo agoHRTXHeron Therapeutics Q2 2026 Conference Call - HERON THERAPEUTICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Heroin Therapeutics second quarter 2026 earnings conference call. At this time all participants are on a listen-only mode. After the speaker's presentation there wil
3mo agoHRTXHeron Therapeutics Announces Second Quarter 2026 Financial ResultsGlobeNewswire– Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF® net revenue grew 35% and APONVIE® net revenue grew 74% year-over-year – Amended credit facility with Hercules Capital: financial
3mo agoHRTXHeron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026GlobeNewswireCARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a
5mo agoHRTXU.S. District Court Issues Decision Regarding CINVANTI® PatentsGlobeNewswireCARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District
6mo agoHRTXHeron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms GuidanceGlobeNewswireQ1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%)Q1 2026 total net revenue of $34.7 millionReached settlement with Baxter Healthcare
6mo agoHRTXHeron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026GlobeNewswireCARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call
8mo agoHRTXHeron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswire– ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and
8mo agoHRTXApproval of Sustol, Nda #022445 (Labeling)FDA Approved DrugsApproval Date: 02/23/2026; Drug Name: Sustol, Nda #022445; Active Ingredients: GRANISETRON; Company: Heron Theraps Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 022445
8mo agoHRTXHeron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026GlobeNewswireCARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call
10mo agoHRTXHeron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 GrowthGlobeNewswireCARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and
11mo agoHRTXHeron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)GlobeNewswireAPONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 ("NK-1") antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral
1y agoHRTXHeron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial ProgressGlobeNewswireGenerated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 millionZYNRELEF® Net
1y agoHRTXHeron Therapeutics Announces Appointment of Thomas Cusack to Board of DirectorsGlobeNewswireCARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board
1y agoHRTXHeron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025GlobeNewswireCARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call
1y agoHRTXHeron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder ValuePR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of...
1y agoHRTXHeron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoHRTXHeron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity ProfilePR NewswireCARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today...
1y agoHRTXHeron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial ProgressPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for...
1y agoHRTXHeron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025PR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled ...
1y agoHRTXHeron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025PR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will...
1y agoHRTXHeron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate UpdatesPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for...
1y agoHRTXHeron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent LitigationsPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company...
1y agoHRTXHeron Therapeutics Announces Appointment of Mark Hensley as Chief Operating OfficerPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark ...
1y agoHRTXHeron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025PR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will...
1y agoHRTXHeron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate UpdatesPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for...
1y agoHRTXHeron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025PR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will...
1y agoHRTXHeron Therapeutics Announces Corporate Headquarters Relocation to Cary, North CarolinaPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of the...
1y agoHRTXU.S. District Court Upholds Validity of CINVANTI® PatentsPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District...
1y agoHRTXApproval of Zynrelef Kit, Nda #211988 (Labeling)FDA Approved DrugsApproval Date: 11/21/2024; Drug Name: Zynrelef Kit, Nda #211988; Active Ingredients: BUPIVACAINE; MELOXICAM; Company: Heron Theraps Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 211988
1y agoHRTXHeron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoHRTXHeron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial GuidancePR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for...
2y agoHRTXHeron Therapeutics Announces Appointment of Michael Kaseta to Board of DirectorsPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of...
2y agoHRTXHeron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024PR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will...
2y agoHRTXHeron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous FluidsPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability...
2y agoHRTXHeron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")PR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and...
2y agoHRTXHeron Therapeutics Announces Appointment of Brett Fleshman as Chief Business OfficerPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...
2y agoHRTXHeron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoHRTXHeron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial GuidancePR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for...
2y agoHRTXHeron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024PR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and...
2y agoHRTXHeron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment SystemPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF®...
2y agoHRTXHeron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")PR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA...
2y agoHRTXHeron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")PR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval...
2y agoHRTXHeron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoHRTXHeron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate UpdatesPR NewswireHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for...